Del Mar Pharmaceuticals Inc.

Presenter: Jeffrey Bacha, President & CEO

Company Information

Company Type: Pharmaceuticals

Development Stage: Private

Company Profile

Del Mar Pharmaceuticals has identified well-characterized small-molecules that have previously demonstrated clinical activity in both orphan and large-market cancer indications.

Company Strategy

Del Mar Pharmaceuticals is focused on rapid development and commercialization of potential new anti-cancer therapies in orphan indications where patients have failed modern biologic therapy.

Intellectual Property

Multiple patents filed

Programs

VAL-083 is a small molecule drug candidate that has undergone extensive Phase II human clinical studies for the treatment of cancer. Del Mar Pharmaceuticals is developing VAL-083 for the treatment of end-stage cancers where patients have failed modern biologic therapy.

Investors

Private Company

Management Team

Founders:
>>Jeffrey A. Bacha, B.Sc., MBA
>>Dr. Dennis Brown, Ph.D.
>>Dr. Bill Garner, M.D.

Presenter Bio

Mr. Jeffrey Bacha, President & CEO: Mr. Bacha is a seasoned executive leader with nearly 20 years of life sciences experience in the areas of operations, strategy and finance for biotechnology, pharmaceutical and medical device companies in Canada, the United States and Europe. His experiences include successful public and private company building from both a start-up and turn around perspective; establishing and leading thriving management and technical teams; and raising capital in both the public and private markets. Mr. Bacha is originally from California. He holds an MBA from the Goizueta Business School at Emory University and a degree in BioPhysics from the University of California, San Diego.

Contact

Del Mar Pharmaceuticals Inc.
Registered Address c/o McCarthy Tetrault Suite 1300 - 777 Dunsmuir Street
Vancouver
BC, Canada
V7Y 1K2

ph: (604) 317 7022
fx: (604) 608 5685

www.delmarpharma.com
jbacha@delmarpharma.com